2 October 2026
Learn about Vitality's GLP-1 obesity support and how it supports successful weight loss through assessments and personalised programs.
8 September 2026
Aspen Pharmacare earnings rose 22% as demand for Eli Lilly's weight-loss drug Mounjaro surged, with the group also eyeing generic semaglutide.
25 August 2026
GLP-1 generics could cut obesity drug costs, challenge illegal sales and expand access as more semaglutide products seek approval.
24 July 2026
The Extensior launch in South Africa offers 15% lower semaglutide prices, but Discovery Health says scheme coverage is unlikely to expand.
23 July 2026
Medicine safety is in focus as the iDexis court case raises questions about compounding, regulation and patient monitoring.
21 July 2026
Aspen Semaglutide Canada gains Health Canada approval, but API supply problems could delay the generic’s commercial launch.
21 July 2026
The Extensior South Africa launch on 27 July, offering patients a lower-cost, authorised semaglutide treatment for type 2 diabetes.
16 July 2026
Sun Pharma’s Generic Semaglutide is now available in South Africa. Explore this new treatment option for type 2 diabetes.
23 June 2026
iDexis semaglutide ban stops the pharmacy group from selling compounded weight-loss medicines while SAHPRA and the SAPC investigate.
1 June 2026
Compounded GLP-1 injections are at the centre of a regulatory dispute. iDexis challenges SAHPRA and SAPC recall orders.
27 May 2026
SAHPRA and SAPC launch an unregistered GLP-1 medicines crackdown, seizing GLP-1 products at a Pretoria pharmacy.
19 May 2026
GLP-1 Drugs In SA could spread as cheaper generics and oral pills arrive, changing food and alcohol demand and pushing premium health trends.